EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs

So Yeong Cheon, Sunghark Kwon

International Journal of Molecular Sciences · 18.03.2023 · 24 (6) · 5821

DOI: 10.3390/ijms24065821 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.03.2023. Verfasst von So Yeong Cheon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Konkuk University, Chungju 27478, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Konkuk University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion gene in non-small-cell lung cancer (NSCLC) was first identified in 2007. As the EML4-ALK fusion protein promotes carcinogenesis in lung cells, much attention has been paid to it, leading to the development of therapies for patients with NSCLC. These therapies include ALK tyrosine kinase inhibitors and heat shock protein 90 inhibitors. However, detailed information on the entire structure and function of the EML4-ALK protein remains deficient, and there are many obstacles to overcome in the development of novel anticancer agents. In this review, we describe the respective partial structures of EML4 and ALK that are known to date. In addition to their structures, noteworthy structural features and launched inhibitors of the EML4-ALK protein are summarized. Furthermore, based on the structural features and inhibitor-binding modes, we discuss strategies for the development of novel inhibitors targeting the EML4-ALK protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansReceptor Protein-Tyrosine KinasesLungOncogene Proteins, FusionProtein Kinase Inhibitors

Stichwörter der Autor:innen

EML4-ALK fusionanaplastic lymphoma kinaseechinoderm microtubule-associated protein-like 4kinase inhibitornon-small-cell lung cancer

Substanzen

Receptor Protein-Tyrosine KinasesAntineoplastic AgentsOncogene Proteins, FusionProtein Kinase InhibitorsEML4-ALK fusion protein, human

Autor:innen und Institutionen

  • Department of Biotechnology, Konkuk University, Chungju 27478, Republic of Korea.
  • Research Institute for Biomedical & Health Science, Konkuk University, Chungju 27478, Republic of Korea.

Förderung

  • Konkuk University

Zitieren

APA

Cheon, S. Y., & Kwon, S. (2023). Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. International Journal of Molecular Sciences, 24(6), 5821. https://doi.org/10.3390/ijms24065821

Vancouver

Cheon SY, Kwon S. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. International Journal of Molecular Sciences. 2023;24(6):5821. doi:10.3390/ijms24065821

BibTeX
@article{Cheon2023,
  author = {Cheon, So Yeong and Kwon, Sunghark},
  title = {Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5821},
  doi = {10.3390/ijms24065821}
}
Kostenlos starten →